Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2

Trine Lisberg Toft-Bertelsen; Mads Gravers Jeppesen; Eva Tzortzini; Kai Xue; Karin Giller; Stefan Becker; Amer Mujezinovic; Bo Hjorth Bentzen; Loren B. Andreas; Antonios Kolocouris; Thomas Nitschke Kledal; Mette Marie Rosenkilde

doi:10.1038/s42003-021-02866-9

Communications Biology (Dec 2021)

Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2

Trine Lisberg Toft-Bertelsen,
Mads Gravers Jeppesen,
Eva Tzortzini,
Kai Xue,
Karin Giller,
Stefan Becker,
Amer Mujezinovic,
Bo Hjorth Bentzen,
Loren B. Andreas,
Antonios Kolocouris,
Thomas Nitschke Kledal,
Mette Marie Rosenkilde

Affiliations

Trine Lisberg Toft-Bertelsen: Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen
Mads Gravers Jeppesen: Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen
Eva Tzortzini: Laboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimioupolis-Zografou
Kai Xue: Department of NMR-based structural biology, Max Planck Institute for Biophysical Chemistry
Karin Giller: Department of NMR-based structural biology, Max Planck Institute for Biophysical Chemistry
Stefan Becker: Department of NMR-based structural biology, Max Planck Institute for Biophysical Chemistry
Amer Mujezinovic: Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen
Bo Hjorth Bentzen: Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen
Loren B. Andreas: Department of NMR-based structural biology, Max Planck Institute for Biophysical Chemistry
Antonios Kolocouris: Laboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimioupolis-Zografou
Thomas Nitschke Kledal: Synklino ApS
Mette Marie Rosenkilde: Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen

DOI: https://doi.org/10.1038/s42003-021-02866-9
Journal volume & issue: Vol. 4, no. 1
pp. 1 – 10

Abstract

Read online

Toft-Bertelsen et al. describe repurposing of anti-influenza drug amantadine and its derivatives for the treatment of SARS-CoV-2. They show that Amantadine, Emodin and Xanthene show significant blockage of ionchannels formed by SARS-CoV-2 which are crucial for its assembly and pathophysiology.

Published in Communications Biology

ISSN: 2399-3642 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science: Biology (General)
Website: https://www.nature.com/commsbio/

About the journal